The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes

Yen Lin Chen, Jiunn Diann Lin, Te Lin Hsia, Frank Chiahung Mao, Chun Hsien Hsu, Dee Pei

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Objective: Impaired insulin sensitivity (SI) and β-cell function are the two main causes of type 2 diabetes (T2D) and are related to low-grade inflammation status. Trivalent chromium has shown to improve SI in our previous study. This might be due to the ability of decreasing interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) shown in animal studies. In the current study, we measured SI, β-cell function, and plasma levels of IL-6 and TNF-α after treatment of chromium chloride (GaCr) in T2D. Research design and methods: Sixty-six patients were randomly assigned to the 20 g of GaCr milk powder studying group or the milk powder placebo group. Oral glucose tolerance test was performed before and after the treatment. The SI and the β-cell function were measured as well. Results: The SI was significantly improved. At the same time, the static insulin responsivity index (Φs) was significantly higher after the treatment (p = 0.003). On the other hand, the dynamic insulin responsivity index (Φd) remained unchanged. Interestingly, a significant decrease in the IL-6 level after the treatment (p = 0.015) was noted. Although there was a trend of decreasing in TNF-α, it was not statistically significant. Finally, there was no significant correlation between the δ-IL-6, SI, and Φd after GaCr treatment. Conclusions: In conclusion, other than the improvement of SI, GaCr could also improve the second phase of insulin responsivity (Φs) and IL-6. However, δ-IL-6 was correlated with neither δ-SI nor δ-Φs which indicated that the improvement of SI and Φs might involve mechanisms other than lower inflammatory effect.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalEuropean Journal of Nutrition
Volume53
Issue number1
DOIs
Publication statusPublished - Feb 2014

Fingerprint

Chromium
Type 2 Diabetes Mellitus
Interleukin-6
Insulin
Powders
Milk
Therapeutics
Glucose Tolerance Test
Plasma Cells
Insulin Resistance
Research Design
Tumor Necrosis Factor-alpha
Placebos
Inflammation

Keywords

  • Chromium
  • Insulin secretion
  • Insulin sensitivity
  • Interleukin-6
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Nutrition and Dietetics

Cite this

The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes. / Chen, Yen Lin; Lin, Jiunn Diann; Hsia, Te Lin; Mao, Frank Chiahung; Hsu, Chun Hsien; Pei, Dee.

In: European Journal of Nutrition, Vol. 53, No. 1, 02.2014, p. 127-133.

Research output: Contribution to journalArticle

Chen, Yen Lin ; Lin, Jiunn Diann ; Hsia, Te Lin ; Mao, Frank Chiahung ; Hsu, Chun Hsien ; Pei, Dee. / The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes. In: European Journal of Nutrition. 2014 ; Vol. 53, No. 1. pp. 127-133.
@article{32b8d5331b55499db16ab0b1d830a54e,
title = "The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes",
abstract = "Objective: Impaired insulin sensitivity (SI) and β-cell function are the two main causes of type 2 diabetes (T2D) and are related to low-grade inflammation status. Trivalent chromium has shown to improve SI in our previous study. This might be due to the ability of decreasing interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) shown in animal studies. In the current study, we measured SI, β-cell function, and plasma levels of IL-6 and TNF-α after treatment of chromium chloride (GaCr) in T2D. Research design and methods: Sixty-six patients were randomly assigned to the 20 g of GaCr milk powder studying group or the milk powder placebo group. Oral glucose tolerance test was performed before and after the treatment. The SI and the β-cell function were measured as well. Results: The SI was significantly improved. At the same time, the static insulin responsivity index (Φs) was significantly higher after the treatment (p = 0.003). On the other hand, the dynamic insulin responsivity index (Φd) remained unchanged. Interestingly, a significant decrease in the IL-6 level after the treatment (p = 0.015) was noted. Although there was a trend of decreasing in TNF-α, it was not statistically significant. Finally, there was no significant correlation between the δ-IL-6, SI, and Φd after GaCr treatment. Conclusions: In conclusion, other than the improvement of SI, GaCr could also improve the second phase of insulin responsivity (Φs) and IL-6. However, δ-IL-6 was correlated with neither δ-SI nor δ-Φs which indicated that the improvement of SI and Φs might involve mechanisms other than lower inflammatory effect.",
keywords = "Chromium, Insulin secretion, Insulin sensitivity, Interleukin-6, Tumor necrosis factor-α",
author = "Chen, {Yen Lin} and Lin, {Jiunn Diann} and Hsia, {Te Lin} and Mao, {Frank Chiahung} and Hsu, {Chun Hsien} and Dee Pei",
year = "2014",
month = "2",
doi = "10.1007/s00394-013-0508-8",
language = "English",
volume = "53",
pages = "127--133",
journal = "European Journal of Nutrition",
issn = "1436-6207",
publisher = "D. Steinkopff-Verlag",
number = "1",

}

TY - JOUR

T1 - The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes

AU - Chen, Yen Lin

AU - Lin, Jiunn Diann

AU - Hsia, Te Lin

AU - Mao, Frank Chiahung

AU - Hsu, Chun Hsien

AU - Pei, Dee

PY - 2014/2

Y1 - 2014/2

N2 - Objective: Impaired insulin sensitivity (SI) and β-cell function are the two main causes of type 2 diabetes (T2D) and are related to low-grade inflammation status. Trivalent chromium has shown to improve SI in our previous study. This might be due to the ability of decreasing interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) shown in animal studies. In the current study, we measured SI, β-cell function, and plasma levels of IL-6 and TNF-α after treatment of chromium chloride (GaCr) in T2D. Research design and methods: Sixty-six patients were randomly assigned to the 20 g of GaCr milk powder studying group or the milk powder placebo group. Oral glucose tolerance test was performed before and after the treatment. The SI and the β-cell function were measured as well. Results: The SI was significantly improved. At the same time, the static insulin responsivity index (Φs) was significantly higher after the treatment (p = 0.003). On the other hand, the dynamic insulin responsivity index (Φd) remained unchanged. Interestingly, a significant decrease in the IL-6 level after the treatment (p = 0.015) was noted. Although there was a trend of decreasing in TNF-α, it was not statistically significant. Finally, there was no significant correlation between the δ-IL-6, SI, and Φd after GaCr treatment. Conclusions: In conclusion, other than the improvement of SI, GaCr could also improve the second phase of insulin responsivity (Φs) and IL-6. However, δ-IL-6 was correlated with neither δ-SI nor δ-Φs which indicated that the improvement of SI and Φs might involve mechanisms other than lower inflammatory effect.

AB - Objective: Impaired insulin sensitivity (SI) and β-cell function are the two main causes of type 2 diabetes (T2D) and are related to low-grade inflammation status. Trivalent chromium has shown to improve SI in our previous study. This might be due to the ability of decreasing interleukin-6 (IL-6) and tumor necrosis factor α (TNF-α) shown in animal studies. In the current study, we measured SI, β-cell function, and plasma levels of IL-6 and TNF-α after treatment of chromium chloride (GaCr) in T2D. Research design and methods: Sixty-six patients were randomly assigned to the 20 g of GaCr milk powder studying group or the milk powder placebo group. Oral glucose tolerance test was performed before and after the treatment. The SI and the β-cell function were measured as well. Results: The SI was significantly improved. At the same time, the static insulin responsivity index (Φs) was significantly higher after the treatment (p = 0.003). On the other hand, the dynamic insulin responsivity index (Φd) remained unchanged. Interestingly, a significant decrease in the IL-6 level after the treatment (p = 0.015) was noted. Although there was a trend of decreasing in TNF-α, it was not statistically significant. Finally, there was no significant correlation between the δ-IL-6, SI, and Φd after GaCr treatment. Conclusions: In conclusion, other than the improvement of SI, GaCr could also improve the second phase of insulin responsivity (Φs) and IL-6. However, δ-IL-6 was correlated with neither δ-SI nor δ-Φs which indicated that the improvement of SI and Φs might involve mechanisms other than lower inflammatory effect.

KW - Chromium

KW - Insulin secretion

KW - Insulin sensitivity

KW - Interleukin-6

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=84895076830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895076830&partnerID=8YFLogxK

U2 - 10.1007/s00394-013-0508-8

DO - 10.1007/s00394-013-0508-8

M3 - Article

C2 - 23494740

AN - SCOPUS:84895076830

VL - 53

SP - 127

EP - 133

JO - European Journal of Nutrition

JF - European Journal of Nutrition

SN - 1436-6207

IS - 1

ER -